Text Size

Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01030497
First received: December 9, 2009
Last updated: August 16, 2012
Last verified: August 2012
History of Changes
  Purpose

The goal of this clinical research study is to learn if using the PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of the body that has, or is suspected to have cancer will give researchers the same or better information about the disease compared to the images taken with a routine PET/CT.

Researchers will compare the images taken using the PEMFlex Solo II to the images taken during your scheduled routine PET/CT scan, as well as any additional routine CT scan(s), magnetic resonance imaging (MRI) scan(s), and/or ultrasound image(s) you may have had within the last 30 days or may have in the next 30 days.


Condition
Head and Neck Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Feasibility Study for Detection of Cervical Lymph Node Metastases With a High-Resolution PET Imaging System in Patients With Known or Suspected Cancers of the Upper Aerodigestive Tract

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Number of peripheral tumor lesions identified in standard PET/CT imaging also identifiable in PEM images. [ Time Frame: 20 minutes for imaging using PEMFlex Solo II, within ± 30 days of standard PET/CT imaging ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: December 2009
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Detailed Description:

If you agree to take part in this study, right after your already scheduled routine PET/CT scan is complete, a study staff member will take you to a separate imaging room located in the same clinic area where your routine PET/CT scan was just performed.

You will then sit in a chair as a study staff member positions the PEMFlex Solo II on either side of the part of the neck that has, or is suspected to have cancer. It will take about 20 minutes to set up the PEMFlex Solo II and take the PET scan images.

Length of Study:

After the PET scan images have been taken using the PEMFlex Solo II, your participation in this study will be over.

This is an investigational study. The PEMFlex Solo II is commercially available for PET scan imaging of the breast. Using the PEMFlex Solo II for imaging any other parts of the body is investigational.

Up to 28 patients will take part in this study. All will be enrolled at M. D. Anderson.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with known or suspected primary cancer of the upper aerodigestive tract or metastatic disease to cervical lymph nodes, over 18 years of age, and scheduled for routine clinical imaging at the PET/CT facility.

Criteria

Inclusion Criteria:

  1. A signed informed consent.
  2. Known or suspected primary cancer of the upper aerodigestive tract, which may be determined by biopsy, physical examination- including upper endoscopy or noninvasive imaging studies including CT, MR, ultrasound, or prior PET.
  3. Known or suspected metastatic disease to cervical lymph nodes based on physical examination, imaging studies or biopsy.
  4. Scheduled for routine clinical imaging at the ACB PET/CT facility.
  5. Participant must be at least 18 years of age.

Exclusion Criteria:

  1. Prior treatment (chemotherapy, radiotherapy) for cancer of the upper aerodigestive tract.
  2. Prior biopsy procedures, including resection of the primary cancer, will not exclude the patient from participation.
  3. Uncontrolled blood glucose levels (>200 mg/dl).
  4. Patient is unable to comprehend the requirements of the study.
  5. Patient is unable to undergo scanning of the neck with the PEM (PET) scanner (due to body habitus, inability to comply with positioning requirements, etc.).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01030497

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Study Chair: Eric Rohren, MD UT MD Anderson Cancer Center
  More Information

Additional Information:
UT MD Anderson Cancer Center website  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01030497     History of Changes
Other Study ID Numbers: 2009-0477
Study First Received: December 9, 2009
Last Updated: August 16, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Cancer
Cervical Lymph Node Metastases
High-Resolution PET Imaging System
Upper Aerodigestive Tract
Head
Neck
 HR PET Imaging System
High-Resolution PET
PET/CT
PEMFlex Solo II
positron emission tomography/computed tomography (PET/CT)

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasm Metastasis
Neoplasms by Site
 Neoplasms
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on May 16, 2013